7月15日，Erasca盘中上涨5.41%，报20.58美元/股，成交额4289.97万美元。
消息面上，公司于7月14日公布了其核心管线泛RAS分子胶药物ERAS-0015在KRAS突变实体瘤中的更新初步一期临床数据，并同步披露注册推进计划：拟于2027年上半年启动支持注册的肺癌临床试验，胰腺癌III期关键性试验亦定于2027年展开。尽管公司同日宣布拟公开发行5亿美元普通股（承销商另有30天超额配售权最高7500万美元），盘后一度因稀释担忧下跌3.5%，但积极的临床进展及明确的注册路径显著提振了市场对公司长期价值的信心，推动股价在次日交易时段走强。
Erasca是一家临床阶段精准肿瘤学公司，专注于为RAS/MAPK通路驱动的癌症患者发现、开发和商业化疗法。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.